Key Highlights

  • Pathkey.AI raised AUD 4.657mn during FY26 through placements, a rights issue and option exercises.
  • Chipforge produced working FPGA designs during FY26 and is planned for deployment into customer environments in FY27.
  • TrialKey continued development and commercialisation, with FY27 focused on marketing, Business development and customer adoption.
  • The company raised a further AUD 2.8mn after year end through a share issue at AUD 0.028 each.

Pathkey.AI Ltd (ASX:PKY) enters FY27 with its two principal AI platforms moving closer to the commercial stage. Chipforge has reached working FPGA designs, while TrialKey continues its clinical-trial forecasting development, giving the company two distinct technology tracks to take into customer environments.

Chipforge Reaches Working FPGA Designs

During FY26, Pathkey.AI produced working designs on the Chipforge platform for FPGA hardware. The platform is designed to translate high-level design intent expressed through text, images, specifications or documents into hardware design code, followed by verification, simulation and FPGA implementation.

FY27 priorities include deploying Chipforge into customer environments, converting demonstrations into paid engagements, securing initial revenue-generating contracts and expanding engineering capability.

TrialKey Continues Its Commercial Build

TrialKey continued development during FY26, with the platform designed to forecast clinical trial success before a trial is conducted. The company progressed its scenario-optimisation engine and tools for monitoring public trial data.

FY27 plans include greater Marketing and business development activity alongside continued platform enhancement and customer adoption.

FY26 Funding and Post-Year-End Capital

Pathkey.AI raised AUD 4,657,016 during FY26 through sophisticated investor placements, a rights issue and option exercises. After year end, 38,654,492 shares were issued on option conversion, raising AUD 966,500 before costs on 10 July 2026.

On 20 August 2026, the company issued 100mn shares at AUD 0.028 each, raising AUD 2.8mn before costs.

FY26 Result Reflects Continued Development

The Group recorded a loss after income tax of AUD 3,652,677 for FY26, compared with AUD 1,447,743 in FY25. Chipforge generated no Revenue during the year as development, demonstrations and early customer engagement remained the focus.

The company identified revenue growth, cost control and additional funding as continuing considerations.

FY27 Shifts Attention Toward Customers

Pathkey.AI is now targeting the conversion of platform demonstrations into paid engagements while continuing development across both products. Chipforge is moving toward customer deployment, and TrialKey is progressing its marketing and business development activity.

The company's FY27 priorities therefore centre on translating technology development into broader commercial adoption.